Phenotypic and Genotypic Characterization of New-onset Type I Diabetes

NAActive, not recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

August 15, 2022

Study Completion Date

June 30, 2027

Conditions
Type1diabetes
Interventions
OTHER

Glucagon

Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).

Trial Locations (1)

1200

Cliniques universitaires Saint-Luc, Brussels

All Listed Sponsors
collaborator

Fonds National de la Recherche Scientifique

OTHER

collaborator

BESPEED

UNKNOWN

lead

Université Catholique de Louvain

OTHER